Mortality Risk Among Patients Hospitalized Primarily for COVID-19 During the Omicron and Delta Variant Pandemic Periods – United States, April 2020-June 2022Article Published on 2022-09-162022-11-16 Journal: Morbidity and Mortality Weekly Report [Category] SARS, 변종, [키워드] adjusted age calculated cause CDC Clinical characteristics COVID-19 COVID-19 hospitalization database deaths Delta early treatment Ethnic groups females Health authority hospital hospitalized COVID-19 patient hospitalized patients In-hospital death in-hospital mortality increase indicated lower mortality male medical condition Medical conditions Mortality mortality risk nonpharmaceutical intervention occurred omicron pandemic Patient patients hospitalized Period proportion public health Racial reported risk United States variant variant of SARS-CoV-2 virus [DOI] 10.15585/mmwr.mm7137a4 PMC 바로가기
SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal studyArticle Published on 2022-09-142022-11-15 Journal: Scientific Reports [Category] SARS, 진단, 치료기술, [키워드] acute respiratory syndrome BNT162b2 vaccine booster dose Cellular immune response changes in conducted coronavirus coronavirus disease COVID-19 demonstrated dose first vaccination follow-up period highest hospital humoral humoral immune response IgG IgG antibody immune response neutralization Neutralizing activity neutralizing antibody no correlation performed receiving SARS-CoV-2 SARS-CoV-2 neutralizing antibodies SARS-CoV-2 spike second vaccination serological Seven significantly sustained T cell T cell assay T cell response T cell responses the vaccine vaccination [DOI] 10.1038/s41598-022-19581-y PMC 바로가기
Effectiveness of rapid SARS-CoV-2 genome sequencing in supporting infection control for hospital-onset COVID-19 infection: Multicentre, prospective studyArticle Published on 2022-09-132022-11-15 Journal: eLife [Category] SARS, 진단, 치료기술, [키워드] 95% CI Admission baseline Capacity changed clinical COG-UK collected conducted COVID-19 COVID-19 infection detect Epidemiology evaluated Evidence extreme global health HAI Health Service Healthcare-associated infection hospital Hospital-acquired infection Human incidence incidence rate Infection infection control Infection prevention Infectious disease Innovation Intervention knowledge Limited Medical Research Council Microbiology molecular Molecular epidemiology MRC NIHR non-randomised trial nosocomial outbreak per-protocol Prospective Study resources respond returned SARS-CoV-2 SARS-CoV-2 genome sequencing sensitivity analysis sequence Sequencing Site statistically significant supported Transmission Trial viral genomics Volume Wellcome Sanger Institute were recorded while [DOI] 10.7554/eLife.78427 PMC 바로가기
Misconceptions Drive COVID-19 Vaccine Hesistancy in Individuals with Inflammatory Bowel DiseaseArticle Published on 2022-09-102022-11-16 Journal: Canadian journal of gastroenterology & hepatology [Category] SARS, 변종, [키워드] 95% CI AOR Characteristics Complete concern COVID-19 COVID-19 vaccination COVID-19 vaccine demographic dose drive effective healthcare worker hospital IBD identify individual Infection Inflammatory bowel disease information Misconception more unwell National pandemic Patient patients Pregnancy public health measure Responder risk the SARS-CoV-2 unique vaccination Vaccine Vaccine hesitancy variable virus variant was used with COVID-19 [DOI] 10.1155/2022/4527844 PMC 바로가기
Coronavirus Vaccination: Spike Antibody Levels in Health Workers after Six Months-A Cross-Sectional StudyArticle Published on 2022-09-102022-11-15 Journal: International Journal of Environmental Research an [Category] SARS, 진단, 치료기술, [키워드] Administered age Anti-spike antibody approved average blood sample booster chemiluminescent immunoassay concentrations COVID-19 criterion cross-sectional elapsed elevated Epidemics exclusion health worker healthcare worker high risk hospital immunoreactivity Immunosuppression Infection infection with SARS-CoV-2 investigated Level MOST mRNA nucleocapsid protein occupational health Pandemics participant Protective required SARS-CoV-2 SARS-CoV-2 pandemic second vaccination significantly spike vaccination Vaccine worker [DOI] 10.3390/ijerph191811422 PMC 바로가기
Prevalence of thrombosis in patients with cancer and SARS-CoV-2 infectionArticle Published on 2022-09-092022-11-16 Journal: Medicina clínica [Category] SARS, 치료기술, [키워드] active cancer added Admitted Patient analyzed association both group Cancer cancer patient Cohort COVID-19 cumulative cumulative incidence detect diagnosed English Factores de Riesgo hospital incidence Incidencia acumulada increased risk Infection medical record Mortality obesity Patient Patients with cancer prothrombotic risk factor SARS-COV-2 infection significant difference Spain Spanish statistically significant study groups thrombosis thrombotic thrombotic event Thrombotic events Trombosis y COVID-19 [DOI] 10.1016/j.medcli.2021.08.002 PMC 바로가기
The complexity of examining laboratory-based biological markers associated with mortality in hospitalized patients during early phase of the COVID-19 pandemic: A systematic review and evidence mapArticle Published on 2022-09-092022-11-15 Journal: PLoS ONE [Category] 바이오마커, 진단, [키워드] 95% CI appraisal association biological marker Biomarker Biomarkers Blood urea nitrogen China Clustering conducted country COVID-19 Critical early phase effect sizes Evidence glomerular filtration rate heterogeneity hospital hospitalized patient hospitalized patients IL-6 include Inflammatory Joanna Briggs Institute laboratory biomarker limit methodology Mortality multiple study overlapping pandemic Patient patients hospitalized patients with COVID-19 Quality renal screened searched Sery SMD standardized mean difference systematic review Web of Science were used with COVID-19 [DOI] 10.1371/journal.pone.0273578 PMC 바로가기
Influence of smoking history on the evolution of hospitalized in COVID-19 positive patients: results from the SEMI-COVID-19 registryObservational Study Published on 2022-09-092022-10-04 Journal: Medicina clínica [Category] SARS, 임상, [키워드] Admission Analysis analyzed Charlson index Clinical characteristics coronavirus disease Course COVID-19 difference discharge events Evolution group hospital Hospitalizado Hospitalized ICU ICU admission in-hospital mortality Inconclusive independent influence intensive care male males median age Mortalidad Mortality multicenter multivariate logistic regression Older Patient patients patients with COVID-19 poor prognosis positive Prevalence previous study readmission remained retrospective cohort study SARS-CoV-2 SARS-COV-2 infection severity Smokers smoking Spanish Tabaquismo. the disease the patient were recorded [DOI] 10.1016/j.medcli.2021.10.011 PMC 바로가기 [Article Type] Observational Study
Acute kidney injury in critically ill COVID-19 infected patients requiring dialysis: experience from India and PakistanArticle Published on 2022-09-082022-11-16 Journal: BMC Nephrology [Category] SARS, 치료기술, [키워드] Acute kidney injury age AKI analysed Cohort collected Continuous Continuous renal replacement therapy COVID 19 patient COVID-19 COVID-19 infected patient Critically ill Critically ill patient critically ill patients detect dialysis died Efficiency form Hemodialysis high mortality hospital ICU India kidney Kidney injury laboratory parameter men Mortality outcome pandemic Patient patients died patients with COVID-19 renal renal replacement therapy required RRT serum albumin slow Slow low efficiency dialysis. the mean therapeutic intervention variable ventilatory support [DOI] 10.1186/s12882-022-02931-3 PMC 바로가기
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialArticle Published on 2022-09-072022-10-06 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 진단, [키워드] 1:1 95% CI Acute kidney injury acute respiratory distress addition all-cause mortality all-cause mortality rate Analysis antibody assigned Belgium Block randomisation Brazil C5a Critically ill defined determine died dose double-blind eligible excluded France Germany hazard ratio hospital hospital discharge IMPROVE intravenously intubation invasive Invasive mechanical ventilation ITT analysis Kaplan-Meier analysis matching placebo mechanically ventilated patient monoclonal antibody Mortality multicentre Netherlands Older one patient outcome PaO participant Patient patient population phase 2 trial phase 3 trial Placebo placebo-controlled Pneumonia primary analysis Primary outcome random assignment randomised Randomly receive receiving reduced Registered reported Research Russia Safe safety analysis SARS-COV-2 infection Septic shock shown significant decrease significantly South Africa Standard of care survival TEAE the placebo group therapy Treatment treatment-emergent adverse event variant vilobelimab viral infections was performed with COVID-19 [DOI] 10.1016/S2213-2600(22)00297-1 PMC 바로가기 [Article Type] Article